Results 301 to 310 of about 206,412 (354)

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Approach to the Management of Gastrointestinal Manifestations in Patients With Phaeochromocytoma and Paraganglioma

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Objective Managing gastrointestinal symptoms in patients with phaeochromocytoma and paraganglioma (PPGL) is challenging due to the risk of catecholaminergic crisis with many commonly prescribed medications, especially in functional tumours.
Monica Majumder   +5 more
wiley   +1 more source

Performance Evaluation of the New High-Sensitivity Cardiac Troponin I Immunoassay on CL-2600i Mindray Analyzer. [PDF]

open access: yesDiagnostics (Basel)
Tomassetti F   +10 more
europepmc   +1 more source

Optimisation of care among patients with diabetes mellitus and acute coronary syndrome through a specialised cardiodiabetes service—A registry study

open access: yesDiabetic Medicine, EarlyView.
Abstract Aims Diabetes mellitus remains a prevalent condition worldwide and a significant risk factor for atherosclerotic cardiovascular disease. Recent evidence suggests the use of glucose‐lowering therapies with cardiovascular benefit in optimising the cardiometabolic profile of patients with type 2 diabetes mellitus.
Muhammad Usman Shah   +6 more
wiley   +1 more source

Biochemical markers of myocardial contusion after blunt chest trauma. [PDF]

open access: yesEur J Trauma Emerg Surg
Bekbossynova M   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy